(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Stopped Sponsor decision, not related to safety concerns

Conditions

• Lung Neoplasms
• Carcinoma, Non-Small-Cell Lung
• Respiratory Tract Neoplasms
• Neoplasms
• Neoplasms by Site
• Lung Diseases
• Respiratory Tract Disease
• Carcinoma, Bronchogenic
• Bronchial Neoplasms
• Adenocarcinoma
• Carcinoma
• Neoplasms by Histologic Type
• Neoplasms, Nerve Tissue
• EGFR T790M
• EGFR C797S
• EGFR L858R
• EGFR Gene Mutation
• EGF-R Positive Non-Small Cell Lung Cancer
• EGFR Exon 19 Deletion
• EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance
• EGFR Activating Mutation
• Protein Kinase Inhibitors
• Antineoplastic Agents
• Thoracic Neoplasms

Interventions

• DRUG: BLU-945
• DRUG: osimertinib

Sponsor

Blueprint Medicines Corporation